CO6140028A2 - Utilizacion de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-4-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos craneales - Google Patents

Utilizacion de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-4-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos craneales

Info

Publication number
CO6140028A2
CO6140028A2 CO09116642A CO09116642A CO6140028A2 CO 6140028 A2 CO6140028 A2 CO 6140028A2 CO 09116642 A CO09116642 A CO 09116642A CO 09116642 A CO09116642 A CO 09116642A CO 6140028 A2 CO6140028 A2 CO 6140028A2
Authority
CO
Colombia
Prior art keywords
piridin
carboxamide
oxido
treatment
cyclopropilmetoxi
Prior art date
Application number
CO09116642A
Other languages
English (en)
Inventor
Philippe Delay-Goyet
Corine Perron
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38819821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6140028(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CO6140028A2 publication Critical patent/CO6140028A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

1.- Utilización de 4-ciclopropilmetoxi-N-(3,5-dicloro-1- oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida en forma de hidrato, de solvato, de base de sal de adición a un ácido, para la preparación de un medicamento destinada al tratamiento de las traumatismos cerebrales.2.- Utilización según la reivindicación 1, caracterizada por que la 4-ciclopropilmetoxi-N-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-Z-carboxamida está en forma de base.
CO09116642A 2007-04-19 2009-10-19 Utilizacion de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-4-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos craneales CO6140028A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0702852A FR2915099B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens

Publications (1)

Publication Number Publication Date
CO6140028A2 true CO6140028A2 (es) 2010-03-19

Family

ID=38819821

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09116642A CO6140028A2 (es) 2007-04-19 2009-10-19 Utilizacion de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-4-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos craneales

Country Status (34)

Country Link
US (1) US9393236B2 (es)
EP (1) EP2146713B1 (es)
JP (1) JP5386476B2 (es)
KR (1) KR101460828B1 (es)
CN (1) CN101663036B (es)
AR (1) AR066105A1 (es)
AT (1) ATE532513T1 (es)
AU (1) AU2008257319B2 (es)
BR (1) BRPI0810423A2 (es)
CA (1) CA2684171C (es)
CL (1) CL2008001135A1 (es)
CO (1) CO6140028A2 (es)
CY (1) CY1112282T1 (es)
DK (1) DK2146713T3 (es)
EA (1) EA015503B1 (es)
ES (1) ES2376023T3 (es)
FR (1) FR2915099B1 (es)
HK (1) HK1141724A1 (es)
HR (1) HRP20120130T1 (es)
IL (1) IL201447A (es)
JO (1) JO2861B1 (es)
MA (1) MA31368B1 (es)
ME (2) ME00938B (es)
MX (1) MX2009011214A (es)
MY (1) MY147207A (es)
NZ (1) NZ580484A (es)
PA (1) PA8776701A1 (es)
PL (1) PL2146713T3 (es)
PT (1) PT2146713E (es)
RS (1) RS52130B (es)
SI (1) SI2146713T1 (es)
TW (1) TWI423800B (es)
UY (1) UY31034A1 (es)
WO (1) WO2008145838A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016500094A (ja) * 2012-11-28 2016-01-07 サノフイ 4−(シクロプロピルメトキシ)−n−(3,5−ジクロロ−1−オキシドピリジン−4−イル)−5−メトキシピリジン−2−カルボキサミドの結晶形態の製造方法およびその結晶形態

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1273326A (en) * 1917-08-22 1918-07-23 George H Bugenhagen Transmission mechanism.
US4193926A (en) 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
EP0711282B1 (en) * 1993-07-28 2002-06-05 Aventis Pharma Limited Compounds as pde iv and tnf inhibitors
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
GB9507297D0 (en) * 1995-04-07 1995-05-31 Rh Ne Poulenc Rorer Limited New composition of matter
US6177077B1 (en) 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
TR200103531T2 (tr) * 1999-06-07 2002-06-21 Warner Lambert Company Trisklik analjezikler
EP1244649B1 (en) 1999-12-23 2005-03-02 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors
CA2439691A1 (en) * 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
AU2003281219A1 (en) 2002-07-02 2004-01-23 Bernard Cote Di-aryl-substituted-ethane pyridone pde4 inhibitors
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
GB2406856B (en) 2003-10-07 2005-10-19 Renovis Inc Amide compounds as ion channel ligands and uses thereof
EP1888528A2 (en) * 2005-06-10 2008-02-20 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US20070021451A1 (en) 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury
FR2915098B1 (fr) 2007-04-19 2009-06-05 Sanofi Aventis Sa Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere

Also Published As

Publication number Publication date
MX2009011214A (es) 2009-11-02
EA200970968A1 (ru) 2010-02-26
KR20090130058A (ko) 2009-12-17
FR2915099A1 (fr) 2008-10-24
ES2376023T3 (es) 2012-03-08
KR101460828B1 (ko) 2014-11-11
CN101663036A (zh) 2010-03-03
MA31368B1 (fr) 2010-05-03
MY147207A (en) 2012-11-14
JO2861B1 (en) 2015-03-15
US20100130553A1 (en) 2010-05-27
TWI423800B (zh) 2014-01-21
RS52130B (en) 2012-08-31
SI2146713T1 (sl) 2012-03-30
JP5386476B2 (ja) 2014-01-15
AU2008257319B2 (en) 2013-07-25
IL201447A (en) 2013-07-31
EP2146713B1 (fr) 2011-11-09
UY31034A1 (es) 2008-11-28
IL201447A0 (en) 2010-05-31
ME01273B (me) 2013-06-20
CN101663036B (zh) 2012-06-20
NZ580484A (en) 2011-06-30
HRP20120130T1 (hr) 2012-03-31
ATE532513T1 (de) 2011-11-15
BRPI0810423A2 (pt) 2014-10-14
AU2008257319A1 (en) 2008-12-04
WO2008145838A2 (fr) 2008-12-04
AR066105A1 (es) 2009-07-22
CL2008001135A1 (es) 2009-01-16
TW200914009A (en) 2009-04-01
JP2010524903A (ja) 2010-07-22
HK1141724A1 (es) 2010-11-19
EP2146713A2 (fr) 2010-01-27
DK2146713T3 (da) 2012-03-05
EA015503B1 (ru) 2011-08-30
ME00938B (me) 2012-06-20
PL2146713T3 (pl) 2012-04-30
CY1112282T1 (el) 2015-12-09
US9393236B2 (en) 2016-07-19
CA2684171C (fr) 2015-12-01
FR2915099B1 (fr) 2009-06-05
PT2146713E (pt) 2012-02-07
WO2008145838A3 (fr) 2009-03-26
CA2684171A1 (fr) 2008-12-04
PA8776701A1 (es) 2008-11-19

Similar Documents

Publication Publication Date Title
PE20221914A1 (es) Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
UY28955A1 (es) Nuevos derivados fluoroglicosídicos de pirazoles, medicamentos que contienen estos compuestos, y el empleo de los mismos
CO6331340A2 (es) Pirrolo-pirimidinas y pirrolo piridinas
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
UY32848A (es) Compuestos heterocíclicos de oxima
MA32272B1 (fr) Inhibiteurs de raf de pyrazole [3,4-b]pyridine
CO6491058A2 (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
EP4233869A3 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
BR112013030909A2 (pt) compostos de imidazopiridina
NZ711424A (en) Pyridine derivatives as soft rock inhibitors
BR112014005389A8 (pt) Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
DOP2012000312A (es) Triazolopiridinas sustituidas
EA201590735A1 (ru) 2-фенил-5-гетероциклил-тетрагидро-2h-пиран-3-аминовые соединения для применения в лечении диабета и связанных с ним расстройств
EA201490630A1 (ru) 6-замещенные 3-(хинолин-6-илтио)[1,2,4]триазоло[4,3-a]пиридины в качестве ингибиторов c-met тирозинкиназы
ECSP066964A (es) Nuevos beta-agonistas, procedimiento para su preparación y su uso como medicamentos
EA201270629A1 (ru) Новые полиморфные формы метил(4,6-диамино-2-[1-(2-фторбензил)-1h-пиразоло[3,4-b]пиридин-3-ил]пиримидин-5-ил)карбамата
AR094241A1 (es) Ciclesonida para el tratamiento de la enfermedad de las vias respiratorias en caballos
UY29883A1 (es) Nuevos beta-agonistas que contienen indol, procedimientos para prepararlos, y su empleo como medicamentos
CO6140028A2 (es) Utilizacion de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-4-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos craneales
HRP20110459T1 (hr) Upotreba 4-ciklopropilmetoksi-n-(3,5-diklor-1-oksidopiridin-4-il)-5-(metoksi)piridin-2-karboksamida u liječenju ozljeda kralježnične moždine
AR066108A1 (es) Utilizacion de 4- ciclopropilmetoxi -n- (3,5- dicloro-1 oxido- piridin- 4-il) -5-(metoxi) piridin-2- carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson
CU20100147A7 (es) Pirrolo-pirimidinas y pirrolo-piridinas
TH118864A (th) การใช้ของ 4-ไซโคลโพรพิลเมธอกซิ-n-(3,5-ไดคลอโร-1-ออกซิโการใช้ 4-ไซโคลโพรพิลเมธอกซิ-n-(3,5-ไดคลอโร-1-ออกซิโด-4-ไพริดิน-4-อิล)-5-(เมธอกซิ)ไพริดีน-2-คาร์บอกซาไมด์ ในการรักษาการบาดเจ็บของกะโหลกศรีษะ